SCNI
Scinai Immunotherapeutics Ltd.NASDAQHealthcare$0.58+1.67%ClosedMarket Cap: $762,912
As of 2026-04-09
Valuation
P/E (TTM)
—
PEG
—
P/B
0.10
P/S
0.58
EV/EBITDA
-0.21
DCF Value
$28.39
FCF Yield
-480.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-202.3%
Operating Margin
-575.3%
Net Margin
-673.2%
ROE
-104.5%
ROA
-75.9%
ROIC
-72.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $260.7K | -530.1% | $-2.8M | $-2.6M | $3.60 | — |
| FY 2025 | $1.3M | -202.3% | $-7.5M | $-8.3M | $0.00 | — |
| Q3 2025 | $277.3K | 0.0% | $-963.5K | $-2.1M | $-1.20 | — |
| Q2 2025 | $386.5K | -164.3% | $-1.9M | $-2.1M | $-1.20 | — |
| Q1 2025 | $386.5K | -164.3% | $-1.9M | $-2.1M | $-1.20 | — |
| Q4 2024 | $206.0K | -81.1% | $-2.3M | $-2.2M | $-8.80 | — |
| FY 2024 | $658.0K | -88.1% | $-8.6M | $4.8M | $6.00 | — |
| Q3 2024 | $168.0K | -148.2% | $-2.4M | $10.5M | $12.40 | — |
| Q2 2024 | $284.0K | -57.7% | $4.0M | $-2.3M | $-3.60 | — |
| Q1 2024 | $0.00 | -Infinity% | $-2.1M | $-2.2M | $-4.40 | — |
| Q4 2023 | $0.00 | -Infinity% | $-1.8M | $-2.3M | $-10.40 | — |
| FY 2023 | $0.00 | -Infinity% | $-9.7M | $-6.5M | $-16.80 | — |